A PBD-dimer containing antibody drug conjugate targeting CCRL2 for high-risk MDS/AML including TP53-mutated disease
A new drug candidate targets a protein overexpressed in the most treatment-resistant leukemias while sparing healthy blood cells, offering hope for a notoriously difficult-to-treat population.
Johns Hopkins group introduces CCRL2 as a novel ADC target selectively overexpressed in high-risk MDS/AML including the TP53-mutated subset — one of the most treatment-refractory leukemia populations with extremely poor outcomes. The anti-CCRL2 PBD-dimer ADC outperformed approved agents in preclinical models while sparing normal hematopoietic progenitors, supporting clinical development.
What the study was
- Study design
- Preclinical translational study (cell lines, primary patient samples, xenograft mouse models)
- Population
- High-risk MDS/AML patients including TP53-mutated subsets (primary samples and PDX models)
- Category
- Drug Development
- Maturity
- Exploratory
- Journal
- Blood Advances
Why it surfaced
Novel ADC target for TP53-mutated MDS/AML (major unmet need); score capped at 5 per non-human-only study rule; Johns Hopkins group with strong translational track record; CCRL2 is a genuinely novel target.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.